CXCR4 and early-onset autosomal dominant Alzheimer disease: Plerixafor (CXCR4 Antagonist): The top-ranked small molecule candidate achieved favorable network scores through CXCR4 engagement, a chemokine receptor implicated in neuroinflammatory signaling, microglial activation, and potentially neurotoxic inflammatory cascades contributing to Alzheimer’s disease progression.